Amneal Pharmaceuticals Stock News

Shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) have earned a consensus rating of Buy from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The [] The post Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Given Average Rating of Buy by Brokerages appeared first on ETF Daily News .

California State Teachers Retirement System lessened its stake in Amneal Pharmaceuticals, Inc. (NYSE:AMRX) by 8.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 137,352 shares of the companys stock after selling 12,187 shares during the quarter. California State Teachers Retirement Systems holdings in Amneal []

Man Group plc purchased a new position in shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) in the second quarter, HoldingsChannel reports. The fund purchased 13,158 shares of the companys stock, valued at approximately $67,000. Several other hedge funds and other institutional investors have also recently modified their holdings of AMRX. Dimensional Fund Advisors LP grew its []

LPL Financial LLC grew its stake in Amneal Pharmaceuticals, Inc. (NYSE:AMRX) by 7.9% in the 2nd quarter, Holdings Channel.com reports. The fund owned 32,622 shares of the companys stock after purchasing an additional 2,383 shares during the quarter. LPL Financial LLCs holdings in Amneal Pharmaceuticals were worth $167,000 as of its most recent SEC filing. []

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for difluprednate ophthalmic emulsion 0.05%, which is the generic version of Durezol® and is used in the treatment of inflammation and pain associated with ocular surgery. “With the approval of difluprednate, a complex ophthalmic suspension product, we conti

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2021 Results - Earnings Call Transcript

Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q3 revenue of $529 million, a marginal increase of 2% Y/Y, missing the consensus of $545.06 million. The increase was driven by Generic product launche

Amneal (AMRX) delivered earnings and revenue surprises of 5.00% and -3.27%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.

The stock price of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) increased by over 10% pre-market. This is why it happened.

Amneal Pharmaceuticals Inc (NYSE: AMRX) announced topline data from the Phase 3 RISE-PD trial evaluating IPX-203 in patients with Parkinson's disease who have motor fluctuations.  Amneal plans to

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q2 2021 Results - Earnings Call Transcript

Amneal (AMRX) delivered earnings and revenue surprises of 38.89% and 1.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $535 million, an increase of 15% Y/Y, beating the consensus of $523.25 million. Sales growth was driven by Generic product launches, spe